Oppenheimer set a $21.00 price target on Constellation Pharmaceuticals (NASDAQ:CNST) in a research report sent to investors on Thursday morning. The firm currently has a buy rating on the stock.
Several other brokerages have also issued reports on CNST. Zacks Investment Research upgraded Constellation Pharmaceuticals from a hold rating to a buy rating and set a $7.75 price objective for the company in a report on Monday, October 15th. Cann initiated coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They set an outperform rating and a $21.00 price objective for the company. BMO Capital Markets initiated coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They set an outperform rating and a $19.00 price objective for the company. Finally, JPMorgan Chase & Co. initiated coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They set an overweight rating and a $17.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Constellation Pharmaceuticals has an average rating of Buy and an average price target of $17.15.
Shares of CNST traded up $0.32 during mid-day trading on Thursday, reaching $6.23. The company’s stock had a trading volume of 17,400 shares, compared to its average volume of 66,507. Constellation Pharmaceuticals has a 1 year low of $5.57 and a 1 year high of $12.21.
Constellation Pharmaceuticals (NASDAQ:CNST) last released its earnings results on Tuesday, August 14th. The company reported ($9.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($9.25). Sell-side analysts anticipate that Constellation Pharmaceuticals will post -2.88 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Constellation Pharmaceuticals stock. TRV GP LLC acquired a new position in shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,034,083 shares of the company’s stock, valued at approximately $20,419,000. Constellation Pharmaceuticals makes up approximately 17.0% of TRV GP LLC’s portfolio, making the stock its 2nd largest holding. TRV GP LLC owned about 11.80% of Constellation Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.01% of the company’s stock.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
Further Reading: Intrinsic Value and Stock Selection
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.